Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients

References

• PenackO, MarchettiM, RuutuT, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7(2):e157–e167. doi:10.1016/s2352-3026(19)30256-x32004485
   PubMed Web of Science ®Google Scholar
• MohtyM, HollerE, JagasiaM, et al. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. Blood. 2020;136(17):1903–1906. doi:10.1182/blood.202000733632756949
   PubMed Web of Science ®Google Scholar
• WolffD, SchleuningM, von HarsdorfS, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(1):1–17. doi:10.1016/j.bbmt.2010.05.01120685255
   PubMed Web of Science ®Google Scholar
• MalardF, HuangXJ, SimJPY. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia. 2020;34(5):1229–1240. doi:10.1038/s41375-020-0804-232242050
   PubMed Web of Science ®Google Scholar
• SpoerlS, MathewNR, BscheiderM, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832–3842. doi:10.1182/blood-2013-12-54373624711661
   PubMed Web of Science ®Google Scholar
• BettsBC, BastianD, IamsawatS, et al. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc Natl Acad Sci U S A. 2018;115(7):1582–1587. doi:10.1073/pnas.171245211529382747
   PubMed Web of Science ®Google Scholar
• ElliEM, BarateC, MendicinoF, PalandriF, PalumboGA. Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. Front Oncol. 2019;9:1186. doi:10.3389/fonc.2019.0118631788449
   PubMed Web of Science ®Google Scholar
• ChoiJ, CooperML, AlahmariB, et al. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One. 2014;9(10):e109799. doi:10.1371/journal.pone.010979925289677
   PubMed Web of Science ®Google Scholar
• CarnitiC, GimondiS, VendraminA, et al. Pharmacologic Inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects. Clin Cancer Res. 2015;21(16):3740–3749. doi:10.1158/1078-0432.CCR-14-275825977345
   PubMed Web of Science ®Google Scholar
• ZeiserR, BurchertA, LengerkeC, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062–2068. doi:10.1038/leu.2015.21226228813
   PubMed Web of Science ®Google Scholar
• KhandelwalP, Teusink-CrossA, DaviesSM, et al. Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant. 2017;23(7):1122–1127. doi:10.1016/j.bbmt.2017.03.02928344057
   PubMed Web of Science ®Google Scholar
• FerreiraAM, Pontes da SilvaCA, PereiraAD, et al. Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center. Bone Marrow Transplant. 2018;53(4):503–506. doi:10.1038/s41409-017-0068-229330403
   PubMed Web of Science ®Google Scholar
• KhouryHJ, LangstonAA, KotaVK, et al. Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. Bone Marrow Transplant. 2018;53(7):826–831. doi:10.1038/s41409-017-0081-529367708
   PubMed Web of Science ®Google Scholar
• ModiB, Hernandez-HendersonM, YangD, et al. Ruxolitinib as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2019;25(2):265–269. doi:10.1016/j.bbmt.2018.09.00330201397
   PubMed Web of Science ®Google Scholar
• Escamilla GomezV, Garcia-GutierrezV, Lopez CorralL, et al. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Bone Marrow Transplant. 2020;55(3):641–648. doi:10.1038/s41409-019-0731-x31700138
   PubMed Web of Science ®Google Scholar
• PrzepiorkaD, LuoL, SubramaniamS, et al. FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist. 2020;25(2):e328–e334. doi:10.1634/theoncologist.2019-062732043777
   PubMed Web of Science ®Google Scholar
• JagasiaM, PeralesMA, SchroederMA, et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020;135(20):1739–1749. doi:10.1182/blood.202000482332160294
   PubMed Web of Science ®Google Scholar
• ZeiserR, von BubnoffN, ButlerJ, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800–1810. doi:10.1056/NEJMoa191763532320566
   PubMed Web of Science ®Google Scholar
• PrzepiorkaD, WeisdorfD, MartinP, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.7581076
   PubMed Web of Science ®Google Scholar
• JagasiaMH, GreinixHT, AroraM, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e381. doi:10.1016/j.bbmt.2014.12.00125529383
   PubMed Web of Science ®Google Scholar
• LeeSJ, WolffD, KitkoC, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21(6):984–999. doi:10.1016/j.bbmt.2015.02.02525796139
   PubMed Web of Science ®Google Scholar
• ZhaoJY, LiuSN, XuLP, et al. Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide. Ann Hematol. 2021;100(1):169–180. doi:10.1007/s00277-020-04273-233159239
   PubMed Web of Science ®Google Scholar
• Gonzalez VicentM, MolinaB, Gonzalez de PabloJ, CastilloA, DiazMA. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: clinical and immunological results. Am J Hematol. 2019;94(3):319–326. doi:10.1002/ajh.2537630536806
   PubMed Web of Science ®Google Scholar
• NeumannT, SchneidewindL, WeigelM, et al. Ruxolitinib for therapy of graft-versus-host disease. Biomed Res Int. 2019;2019:8163780. doi:10.1155/2019/816378030956985
   PubMed Web of Science ®Google Scholar
• DangSH, LiuQ, XieR, et al. Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: results from a retrospective study on 38 Chinese patients. World J Clin Cases. 2020;8(6):1065–1073. doi:10.12998/wjcc.v8.i6.106532258077
   PubMed Web of Science ®Google Scholar
• MoiseevIS, MorozovaEV, BykovaTA, et al. Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults. Bone Marrow Transplant. 2020;55(7):1379–1387. doi:10.1038/s41409-020-0834-432071418
   PubMed Web of Science ®Google Scholar
• UygunV, KarasuG, DalogluH, et al. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: a single-center experience. Pediatr Blood Cancer. 2020;67(4):e28190. doi:10.1002/pbc.2819031981413
   PubMed Web of Science ®Google Scholar
• YangW, ZhuG, QinM, et al. The effectiveness of ruxolitinib for acute/chronic graft-versus-host disease in children: a retrospective study. Drug Des Devel Ther. 2021;15:743–752. doi:10.2147/DDDT.S287218
   Web of Science ®Google Scholar
• ZeiserR, PolverelliN, RamR, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021;385(3):228–238. doi:10.1056/NEJMoa203312234260836
   PubMed Web of Science ®Google Scholar
• IsbernerN, KrausS, GrigoleitGU, et al. Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial. Cancer Chemother Pharmacol. 2021;88(6):973–983. doi:10.1007/s00280-021-04351-w34505930
   PubMed Web of Science ®Google Scholar
• LinR, LiuQ. Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2013;6:94. doi:10.1186/1756-8722-6-9424341630
   PubMed Web of Science ®Google Scholar
• WuH, ShiJ, LuoY, et al. Evaluation of ruxolitinib for steroid-refractory chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplantation. JAMA Netw Open. 2021;4(1):e2034750. doi:10.1001/jamanetworkopen.2020.3475033502484
   PubMed Web of Science ®Google Scholar